Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1987 1
1988 1
1989 1
1993 4
1994 4
1995 2
1996 1
1997 4
1998 8
1999 6
2000 7
2001 6
2002 3
2003 9
2004 5
2005 4
2006 10
2007 3
2008 9
2009 7
2010 9
2011 5
2012 26
2013 23
2014 20
2015 32
2016 29
2017 35
2018 49
2019 86
2020 80
2021 60
2022 63
2023 47
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

603 results

Results by year

Filters applied: . Clear all
Page 1
SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy.
Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, Bordignon L, Masri A, Serenelli M, Urey M, Musumeci B, Cipriani A, Canepa M, Badr-Eslam R, Kronberger C, Chimenti C, Zampieri M, Allegro V, Razvi Y, Patel R, Ioannou A, Rauf MU, Petrie A, Whelan C, Emdin M, Metra M, Merlo M, Sinagra G, Hawkins PN, Solomon SD, Gillmore JD, Fontana M. Porcari A, et al. J Am Coll Cardiol. 2024 Jun 18;83(24):2411-2422. doi: 10.1016/j.jacc.2024.03.429. J Am Coll Cardiol. 2024. PMID: 38866445
BACKGROUND: Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in randomized clinical trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i). ...SGLT2i treatment was associated with reduced risk of HF hospitalization and cardiovascular and all-c …
BACKGROUND: Transthyretin cardiomyopathy (ATTR-CM) was an exclusion criterion in randomized clinical trials of sodium-glucose …
Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis.
Saro R, Allegro V, Merlo M, Dore F, Sinagra G, Porcari A. Saro R, et al. Heart Fail Clin. 2024 Jul;20(3):343-352. doi: 10.1016/j.hfc.2024.03.005. Epub 2024 Apr 4. Heart Fail Clin. 2024. PMID: 38844305 Review.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a relatively prevalent cause of morbidity and mortality. ...Second-generation drugs for silencing are currently under investigation in randomized clinical trials. In vivo gene editing of transthyretin has been …
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a relatively prevalent cause of morbidity and mortality. ...Second-generation drugs …
Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Capovilla TM, Lalario A, Rossi M, Porcari A, Aimo A, Limongelli G, Emdin M, Merlo M, Sinagra G. Capovilla TM, et al. Heart Fail Clin. 2024 Jul;20(3):333-341. doi: 10.1016/j.hfc.2024.03.007. Epub 2024 Apr 12. Heart Fail Clin. 2024. PMID: 38844304 Review.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the myocardial extracellular deposition of amyloid fibrils formed from the dissociation of TTR tetramer into monomers. ...Tafamidis is a safe and effective drug in reducing symptoms, hospitalization and mor …
Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the myocardial extracellular deposition of amyloid fibrils formed …
Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy.
Kuyama N, Takashio S, Oguni T, Yamamoto M, Hirakawa K, Ishii M, Hanatani S, Oda S, Matsuzawa Y, Usuku H, Yamamoto E, Hirai T, Ueda M, Tsujita K. Kuyama N, et al. J Am Heart Assoc. 2024 May 21;13(10):e034518. doi: 10.1161/JAHA.124.034518. Epub 2024 May 18. J Am Heart Assoc. 2024. PMID: 38761073 Free article.
BACKGROUND: Although tafamidis treatment improves prognosis in patients with wild-type transthyretin amyloid cardiomyopathy, an optimal surrogate marker monitoring its therapeutic effect remains unclear. This study investigated the association between changes in cardiac bi …
BACKGROUND: Although tafamidis treatment improves prognosis in patients with wild-type transthyretin amyloid cardiomyopathy, an optim …
Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro.
Dias M, Pinto LF, Pinto MV, Gervais R, Accioli P, Amorim G, Guedes M, Gomes CP, Pedrosa RC, Waddington-Cruz M. Dias M, et al. Arq Neuropsiquiatr. 2024 Apr;82(4):1-7. doi: 10.1055/s-0044-1781463. Epub 2024 Apr 5. Arq Neuropsiquiatr. 2024. PMID: 38579737 Free PMC article.
Mutations in the transthyretin (TTR) gene cause the TTR protein to destabilize, misfold, aggregate, and deposit in body tissues, which makes ATTRv a disease with heterogeneous clinical phenotype. OBJECTIVE: To describe the long-term efficacy and safety of inotersen therapy …
Mutations in the transthyretin (TTR) gene cause the TTR protein to destabilize, misfold, aggregate, and deposit in body tissues, which makes …
Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy.
Sanso MAR, Rodriguez AR, Vicente LM, Sevilla T, Garro CB, Martín JF, Vicente AA, de la Prida MM, Dávila LG, Vázquez LG, Valle FM, Pons CC, Bau AF, Barroso EC, López IL, González-Moreno J. Sanso MAR, et al. Med Clin (Barc). 2024 May 17;162(9):e27-e32. doi: 10.1016/j.medcli.2024.01.008. Epub 2024 Mar 30. Med Clin (Barc). 2024. PMID: 38556397 English, Spanish.
METHODS: This is a national multicenter study in which patients with V30M A-ATTR related PN treated with tafamidis for at least 1 year were included. Clinical, demographic, analytical and neurophysiological variables were analysed. ...Better treatment response was shown in …
METHODS: This is a national multicenter study in which patients with V30M A-ATTR related PN treated with tafamidis for at least 1 year were …
Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short-term efficacy and safety.
Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, Bampatsias D, Maurer MS. Lang FM, et al. Eur J Heart Fail. 2024 Apr;26(4):938-947. doi: 10.1002/ejhf.3198. Epub 2024 Mar 15. Eur J Heart Fail. 2024. PMID: 38488292
AIMS: Despite their potential, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have not been well-studied in transthyretin amyloid cardiomyopathy (ATTR-CM) as randomized trials have excluded patients with this morbid disease. ...CONCLUSION: Sodium-glucose cotrans …
AIMS: Despite their potential, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have not been well-studied in transthyretin amyloid
Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.
Grogan M, Davis MK, Crespo-Leiro MG, Sultan MB, Gundapaneni B, Stedile Angeli F, Hanna M. Grogan M, et al. Eur J Heart Fail. 2024 Mar;26(3):612-615. doi: 10.1002/ejhf.3190. Epub 2024 Mar 4. Eur J Heart Fail. 2024. PMID: 38439606 Clinical Trial.
AIMS: To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and lon …
AIMS: To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin am
In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo.
Masri A, Van Spall HGC. Masri A, et al. Ann Intern Med. 2024 Mar;177(3):JC30. doi: 10.7326/J24-0004. Epub 2024 Mar 5. Ann Intern Med. 2024. PMID: 38437698 Clinical Trial.
Maurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. ...
Maurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloid …
603 results